A treatment programme is written in a global guide, which does not mean that it can be placed on a prescription for chinese patients. The distance between them is sometimes much longer than expected。
From 11 to 14 june, the thirty-first annual academic conference of the chinese medical association on dermatological diseases (csd2026) was held at the international conference centre in the capital. The theme of the annual session was “academic leadership, international integration”, bringing together 30 international experts, and the general assembly's new focus on diseases and on priority drugs, bringing the regularized treatment of tan spots to the spotlight. The first piece of yellow-coloured masturbation was held in the form of a special stand (t19 in the west of the b1 museum) and a midday symposium。
It's an old problem
In 1975, prof. Kligman proposed a three-pronged external treatment programme for verbola, consisting of hydrogen, vinyl acid and sugary cortex hormones. Over the following half-century, the programme was recommended as a line-line for a global multi-country guide/consensus with medium-heavy brunette, and its evidence-based basis has been repeatedly validated by numerous clinical studies. In china, the consensus of experts on yellow-brown care (2021 edition) and the international expert consensus 2025 recommend treatment at the highest level for the sanctuary excerpt programme。
But back in the clinic, it wasn't that simple. There is a chronic shortage of finished drugs produced strictly in accordance with this formula. Doctors are able to prescribe prescriptions, but they are unable to provide a ready-made drug — three raw material ointment — which is based on experience and manual allocation, a sense of hand, and a degree of balance based on patience. A treatment path that has been tested for almost 50 years has been stuck between the prescription pen of a chinese doctor and the patient's medicine box for too long。
At this annual session, this clinical pain has been the focus of the thematic discussion. During the midday session on 12 june, prof. Liu, general hospital of tianjin medical university, shared clinical practice data on furi mio: treatment was visible for four weeks, with an efficiency of 61. 6 per cent for eight weeks, and the efficacy was equivalent to that of the original research product and significantly superior to a single hydrogen formulation. Professor liu emphasized that fulemax had achieved a three-pronged outcome through a “black-promoting-anti-inflammation” synergy mechanism, and noted that clinical use was subject to five main principles — comprehensive pre-medicine screening and the removal of taboos; close skin reaction monitoring in medications; strict control of the treatment process over four to eight weeks, with gradual reduction of withdrawals after achieving results; the use of wet and sunscreening as the cornerstone of the treatment process; and regular follow-up, dynamic assessment of efficacy and safety in the use of medicines. It is only by following these principles and using this “kind standard” that patients can truly benefit。
Prof. Liu chuang, general hospital of tianjin medical university, shared the scene figure
B1 t19, an exchange on standard programmes
At the t19 exhibition in the western section of b1, the professional exchange atmosphere in fulemax differs from the usual branding. The dermatologists who came to exchange were concerned with clinical data, adaptive boundaries and drug response management strategies. These are precisely the core topics of a standardized drug clinically. According to the conference, over 1,000 dermatologists were present at the stand to gain insight into the clinical advantages of the product and the normative application programme。
The data from the third phase of the clinical trial, twilight triad of chromosomal plaster, which was approved as the first domestic deposit, showed that it had the same therapeutic effect as the original drug; a 24-week observation study (bhawanj, et al. 2009) confirmed that the standardized use did not increase the risk of skin contraction. On the formulation, 0. 01 per cent fluorine is designed at an easy and precise concentration to control hormone-related risks at a lower level while ensuring anti-inflammation synergy。
In the afternoon of 12 june, the fulemax symposium was held on the theme “evident evidence-based, the future of fukui” in breakout area 7. On the occasion, professor lin chi-chul, surgeon hospital, south medical university, and professor tsing zhong liu shared their academic experiences on the characteristics of the skin-infection pathogen and the normative treatment of twilight. Prof. Liu chong read in detail the mechanisms and treatment scenes of furi mi-chan in conjunction with the clinical case, and there was a live and interactive atmosphere。
From a research and development path, it is not the “quick follow-up” model that fulemax walked. Zhang tao, deputy director-general of vernor's medicine, described the team's judgement in previous interviews as follows: “if you want to do it, do it best and it's really useful”. Over the course of more than a decade, from the 2002 project to its final approval, there has been a rigorous alignment of the conformity evaluation, and the third phase of clinical trials has progressed difficultly during the epidemic. “the moment of discovery was peaceful and emotional. It's been a decade and a decade, and it's been a long time."
The academic discussions at this annual session have shown more clinical practitioners the feasibility of normative treatment. A 50-year-tested treatment framework is no longer a text in a textbook, but a touchable ointment. Time will answer how many patients it will change。
